ArticleInflammation2026
Identifying Crucial Genes Associated with Pyroptosis in Lupus Nephritis.
Article in Inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Lupus nephritis (LN), a severe manifestation of systemic lupus erythematosus, involves immune complex deposition, inflammation, and kidney damage. Recent studies indicate that pyroptosis, a pro-inflammatory cell death process, drives renal injury in LN. This study intended to identify key pyroptosis-related genes in LN using datasets from the GEO database, encompassing glomerular, tubulointerstitial, and whole kidney tissues from LN patients. Identified differentially expressed genes related to pyroptosis and created a predictive model using univariate and LASSO regression analysis. LN patients were classified into subtypes through consensus clustering. Immune microenvironment characteristics and hallmark pathways were further analyzed. Using the WGCNA, key gene modules and hub genes were recognized, followed by an analysis of their clinical relevance and distribution patterns using the Nephroseq database and scRNA-seq data. Cellular experiments were conducted to validate the findings. We identified 26 differentially expressed pyroptosis-related genes in LN glomeruli and created a 10-gene model with high diagnostic accuracy (AUC: 0.968 for tubulointerstitium, 0.990 for whole kidney). Consensus clustering divided LN into two subtypes: subtype1, characterized by inflammation and immune activation, and subtype2, characterized by cellular metabolism. WGCNA highlighted the grey60 module linked to subtype1, and identified GBP2 and EIF2AK2 as hub genes. Cellular experiments showed that GBP2 and EIF2AK2 were upregulated in LPS-stimulated macrophages and glomerular endothelial cells, and their siRNA-mediated knockdown triggered a decline in pyroptosis-related marker expression, implying their possible role as therapeutic targets for modulating pyroptosis in LN. In conclusion, GBP2 and EIF2AK2 show potential as candidate molecules for targeted therapy in LN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.